Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma

Exclusion Criteria

• •1. Histological histological diagnosis of squamous cell carcinoma (adenosquamous carcinoma mainly including squamous cell carcinoma), carcinoid, undifferentiated carcinoma or other unclassified carcinoma;
• •2. Patients with HER2-positive status are excluded;
• •3. Patients with distant metastases other than primary gastric cancer (any M1 stage);
• •4. Patients with contraindications (laparoscopic surgery, open surgery, neoadjuvant chemotherapy);
• •5. Patients who can not undergo radical surgical resection (D2 radical resection);
• •6. Previous antitumor therapy (including chemotherapy, radiotherapy, molecular targeted therapy and hormone therapy);
• •7. Previously received immunological drugs such as PD-1/PD-L1, CTLA-4 or other immunological or molecular targeted therapies;
• •8. When virological testing prior to screening showed any of the following:
• •1. patients with active hepatitis (HBV DNA≥1\*103 copies or ≥200IU/mL);
• •2. Anti - HCV positive;
• •3. HIV positive;
• •9. Patients or their families refused to sign this informed consent form to participate in the study.